Fri, Aug 29, 2014, 2:40 AM EDT - U.S. Markets open in 6 hrs 50 mins


% | $
Quotes you view appear here for quick access.

Cempra, Inc. Message Board

pharmajedi 4 posts  |  Last Activity: Aug 27, 2014 2:03 PM Member since: Feb 2, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • pharmajedi by pharmajedi Jun 20, 2014 4:07 PM Flag

    Valuation is simply to high to sustain.

  • Curious how folks feel about the new P2 lung cancer trial. Is this confidence that STS or Pancreatic P3 trials are going well and will meet end points or is this THLD management way of safe guarding against a negative outcome at the expense of shareholders? Small companies like this often use the latter strategy as a way to continue ops and their high salaries.....

  • Reply to

    Study change PFE-00345439

    by galaxy_100t Aug 25, 2014 6:17 PM
    pharmajedi pharmajedi Aug 27, 2014 1:52 AM Flag

    This is one of the most undervalued bio plays with little risk IMO. Essentially all P1 complete with high likely hood of meeting end points for such small cohorts. Manufacturing and stability concerns would have been mitigated prior to starting these additional P1s. Pfizer has stated it intends to move forward and refile. FDA now seeks out abuse deterrent products. King and Pfizer have already validated the nPV for Remoxy amongst competition and have done due diligence on IP. Low risk with low price/valuation, seems like a no brainier. I have made my bets, solid play here and look forward to next 6-12 months to triple my investment. Ptie is not a speculative play anymore (but rather a great investment) due to risk/reward profile. Now is the time to invest prior to news being released!

    Sentiment: Strong Buy

  • Reply to

    Bye 9's forever..............

    by schroe_us Aug 26, 2014 11:04 AM
    pharmajedi pharmajedi Aug 27, 2014 2:03 PM Flag

    nope; just sold short....will see 9s and 8s again shortly!

10.31-0.32(-3.01%)Aug 28 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.